Homology is a genetic medicines company translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The combination of a management team that has successfully developed and commercialized rare disease therapies, and a new multidimensional technology platform uniquely positions the Company to move beyond the current limitations of gene therapy and editing approaches to improve patient care. Homology Medicines has built foundational intellectual property on gene editing and gene therapy using vectors derived from naturally occurring human adeno-associated viruses (AAVs). The Company's technology is precise, on-target and highly efficient for in vivo editing of genetic mutations. The unique team and technology create a significant opportunity for Homology to rapidly advance a diverse pipeline of new medicines that address and potentially cure the underlying cause of genetic diseases.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
05/02/16	$43,500,000	Series A	5AM Ventures ARCH Venture Partners Deerfield Management Company, L.P. Temasek	undisclosed
08/01/17	$83,500,000	Series B	5AM Ventures Alexandria Venture Investments ARCH Venture Partners Deerfield Management Company, L.P. Fidelity Management & Research Company HBM Healthcare Investments Maverick Ventures Novartis Rock Springs Capital Temasek Vida Ventures Vivo Capital	undisclosed